|A 419259 trihydrochloride LCK inhibitor, orally available|
Sample solution is provided at 25 µL, 10mM.
Publications citing ApexBio Products
|Cas No.||1435934-25-0||SDF||Download SDF|
|Chemical Name||7-((1r,4r)-4-(4-methylpiperazin-1-yl)cyclohexyl)-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine trihydrochloride|
|Canonical SMILES||CN1CCN([[email protected]@]2([H])CC[[email protected]@](N3C=C(C(C3=NC=N4)=C4N)C5=CC=C(OC6=CC=CC=C6)C=C5)([H])CC2)CC1.Cl.Cl.Cl|
|Solubility||Soluble in DMSO||Storage||Store at -20°C|
|Physical Appearance||A crystalline solid||Shipping Condition||Evaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request|
|General tips||For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.|
A 419259 trihydrochloride is an orally available inhibitor of lck with IC50 value of 15 nM .
Lck is a src family tyrosine kinase. Inhibition of this enzyme results in a prevention of T-cell activation and provides an application for treating T-cell dependent processes such as autoimmune and inflammatory diseases. A 419259 trihydrochloride is screened out by its potent inhibitory activity against the recombinant lck (64–509) with IC50 value of 15nM. It is also a selective inhibitor. It shows inactive against a panel of other kinases including cMet, IGFR, PKC and PDGFR. Besides that, A 419259 trihydrochloride is found to inhibit the production of IL-2 with IC50 value of 25nM in Jurkat cells. Moreover, administration of A 419259 trihydrochloride reduces IL-2 production in mice with ED50 value of 2.5 mg/kg. A 419259 trihydrochloride also has efficacy of the antigen specific T-Cell immune response. Administration of this compound inhibits IFN-γ production during the in vivo priming phase .
 Calderwood D J, Johnston D N, Munschauer R, et al. Pyrrolo [2, 3-d] pyrimidines containing diverse N-7 substituents as potent inhibitors of Lck. Bioorganic & medicinal chemistry letters, 2002, 12(12): 1683-1686.